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While significant advances have been made in the prevention and treatment of malaria in recent years, these
successes continue to fall short of the World Health Organization (WHO) goals for malaria control and elimination.
For elimination strategies to be effective, limited disease transmission, achieved through rapid reduction in the
infectious parasite reservoir and decreased gametocyte carriage, will be critical. Artemisinin-based combination
therapy (ACT) forms the cornerstone of WHO-recommended treatment for uncomplicated Plasmodium falciparum
malaria, and in combination with other effective interventions will undoubtedly play a vital role in elimination
programmes. The gametocytocidal properties of artemisinins are a bonus attribute; there is epidemiological evidence
of reductions in malaria incidence and transmission in African regions since the introduction of these agents. Many
studies and analyses have specifically investigated the effects of the ACT, artemether-lumefantrine (AL) on gametocyte
carriage. In this systematic review of 62 articles published between 1998 and January 2014, the effects of AL on
gametocyte carriage and malaria transmission are compared with other artemisinin-based anti-malarials and
non-ACT. The impact of AL treatment of asymptomatic carriers on population gametocyte carriage, and the
potential future role of AL in malaria elimination initiatives are also considered. Despite the inherent difficulties in
comparing data from a range of different studies that also utilized different diagnostic approaches to assess
baseline gametocyte counts, the gametocytocidal effect of AL was proportionately consistent across the studies
reviewed, suggesting that AL will continue to play a vital role in the treatment of malaria and contribute to
clearing the path towards malaria elimination. However, the specific place of AL is the subject of much ongoing
research and will undoubtedly be dependent on different demographic and geographical scenarios. Utilizing
ACT, such as AL, within malaria elimination strategies is also associated with a number of other challenges, such
as balancing potential increased use of ACT (e g, treatment of asymptomatic carriers and home-based treatment)
with rational use and avoidance of drug resistance development.
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From malaria control to elimination
Between 2000 and 2012 estimated malaria mortality
rates across all age groups dropped by 42% and 49% glo-
bally and in Africa, respectively, and deaths decreased by
51% in Africa in children < five years of age [1]. Model-
ling estimates indicate that between 2000 and 2012, 3.3
million malaria deaths were averted, 90% of which were
estimated to be in children < five years in sub-Saharan
Africa [1]. However, the rate of decline in estimated mal-
aria mortality slowed between 2011 and 2012. This isCorrespondence: makanga@edctp.org
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unless otherwise stated.partially attributed by the World Health Organization
(WHO) to insufficient funds to provide insecticide-treated
bed nets (ITNs) to countries with ongoing transmission of
the disease, and a relatively slow roll-out and interrupted
supplies of preventative therapy to children < five years
and pregnant women in recent years [1]. This may also
have been partly due to ongoing interruptions in the
supply chain of artemisinin-based combination therapy
(ACT) to populations in need [2,3], as well as the rela-
tively slow global roll-out of intravenous artesunate.
Encouragingly, in 2013, 136 million nets were delivered
to malaria-endemic countries and this number looks set
to increase further throughout 2014 [1]. In addition, in-
creasing access to WHO-recommended ACT has been. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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creased from 76 million in 2006 to 331 million in 2012 [1].
Despite all of the above measures, during 2012 there
were an estimated 207 million cases of malaria, resulting
in approximately 627,000 malaria deaths. An estimated
3.4 billion individuals remain at risk of malaria, primarily
in Africa (where 80% of cases occur) and Southeast Asia
[1]. Therefore, while significant advances have been
made in managing malaria in recent years, these suc-
cesses continue to fall short of WHO goals for malaria
control and elimination (i e, to reduce global malaria
deaths to near zero by end of 2015; to reduce global
malaria cases by 75% by end of 2015; and to eliminate
malaria by end of 2015 in ten new countries since 2008,
including in the WHO European Region) [1].
A WHO global technical strategy for malaria control
and elimination is currently planned for the period 2016
to 2025, in addition to a global plan to control and elim-
inate Plasmodium vivax malaria [4]. Moreover, several
other public health intervention strategies are also being
implemented [5-7]. As countries move towards malaria
elimination, limiting transmission of the disease will be
critical. In order to achieve this, treatment will need to
be able to rapidly reduce the infectious parasite reser-
voir, decrease gametocyte carriage and thus reduce in-
fectiousness to mosquitoes.
Plasmodium life cycle and the role of gametocytes in
transmission
The Plasmodium life cycle and targets of ACT and older
generation, non-ACT anti-malarials are illustrated in
Figure 1 [8]. Key to the transmission of malaria is the
differentiation within red blood cells of a small number
of haploid asexual parasites into male and female game-
tocytes. Following their ingestion by the mosquito, these
male and female gametes fuse to form a zygote and then
an oocyst. Multiple rounds of DNA replication result in
the production of thousands of sporozoites that are trans-
mitted to humans via the mosquito’s salivary glands, and
the cycle begins again. Gametocytes are also integral to
the transmission and propagation of disease resistance;
compared with drug-sensitive infections, resistant infec-
tions are associated with increased rates of recrudescence
and slower initial treatment responses, both of which in-
crease gametocyte densities. This suggests that increased
gametocyte carriage in infections caused by resistant para-
sites results in a transmission advantage that ultimately
helps to drive the spread of resistance [9,10].
Several factors are likely to influence the appearance
of gametocytes at presentation, including age, host im-
mune response (including co-infection with other patho-
gens), host anaemia, insecticide spraying, and mass drug
administration [11]. Risk factors that have been found to be
specifically associated with gametocytaemia after treatmentin studies include trimethoprim-sulphamethoxazole (TS)
prophylaxis [12], increased age (in children) [12], recurrent
parasitaemia [12], duration of parasitaemia [13], the pres-
ence of any degree of anaemia [13,14], gametocytaemia
at enrolment [15], and treatment with artesunate (AS) or
artesunate-mefloquine (AS-MQ) compared with other ACT
[artemether-lumefantrine (AL), Coartem®, or artesunate-
amodiaquine (AS-AQ)] [15].
While gametocyte carriage is integral to the transmis-
sion of malaria, it is important to note that their pres-
ence and detection in peripheral blood does not
necessarily equate to infectivity. In this respect, although
there is an overall positive correlation between gameto-
cyte density and the mosquito infection rate, this correl-
ation is not particularly strong. One reason for this is
likely to be due to the presence of immature gameto-
cytes. Another reason may be due to the poor sensitivity
of microscopy for detecting gametocytes. In this regard,
gametocytes are invariably detected in fewer than 50% of
clinical and asymptomatic Plasmodium falciparum in-
fections. In fact, the gametocytes are likely to be present
in the majority of infections, just at low densities that
evade microscopic detection [11]. This point is further
discussed in this review.
Artemisinin-based combination therapy
ACT forms the cornerstone of WHO-recommended
treatment for uncomplicated P. falciparum malaria [16],
and will undoubtedly play a vital role in malaria elimin-
ation strategies [7]. An important feature of artemisinin
derivatives, that complements their high efficacy against
asexual plasmodium parasites, is their gametocytocidal
properties; ACT can shorten the duration of gametocyte
carriage by approximately four-fold [17]. There is epi-
demiological evidence of reductions in malaria transmis-
sion and incidence in various African regions since the
introduction of ACT [18] when used together with in-
door residual spraying and ITNs. In a pooled analysis of six
randomized trials, patients treated with ACT had signifi-
cantly lower gametocytaemia than non-ACT treatment
during 28 days of follow-up, and this was associated with
reduced human to mosquito transmission [19]. Similarly,
in a study in Northwest Thailand, gametocyte reduction
following ACT translated into a six-fold decrease in para-
site transmission (reviewed in [18]). Field studies have
shown that artemisinin treatment significantly reduced
gametocyte carriage compared with other agents and this
effect was variable depending on geographical region, level
of malaria endemicity and access to treatment [8].
AL, which was originally developed and investigated in
China [20], was approved by Swissmedic in 1999 and by
the U.S. Food and Drug Administration in 2009 for the
treatment of uncomplicated P. falciparum malaria. There
is now extensive clinical experience with AL in patients of
Figure 1 Life cycle of Plasmodium falciparum. Artemisinin acts at an early stage of the erythrocytic stage of the parasite’s life cycle and is also
effective against the gametocyte stage, thereby potentially interrupting transmission of malaria [8]. (Sourced from Hommel M 2008, with permission [8]).
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of the most widely used ACT. In addition to the key clin-
ical trials that led to the drug’s approval, numerous inde-
pendent studies (>60, including >12,000 subjects) have
supported the clinical efficacy of this agent, and many
studies and analyses have specifically investigated the ef-
fects of AL on gametocyte carriage.
This systematic review describes the effects of AL on
gametocyte carriage and transmission of malaria, and
compares the effects of AL with other artemisinin-based
anti-malarials. It also discusses the impact of AL treat-
ment of asymptomatic carriers on population gameto-
cyte carriage, and considers the potential future role of
AL in malaria elimination strategies.
Methods
Search strategy and selection criteria
References for this review were identified through searches
of the following databases that were conducted on 12
September, 2013 for the period 1995 to 2013, and on 31
January, 2014 for the period 12 September to 31 January
2014: Embase (1996 to 10 September, 2013), BIOSIS
Previews (1995 to January 2013), EBM Reviews - Cochrane
Database of Systematic Reviews (2005 to December 2011),Ovid MEDLINE® without Revisions (1996 to August
2013), Ovid MEDLINE® In-Process & Other Non-Indexed
Citations (January 2012), Ovid MEDLINE® Daily Update
(January 2012), Ovid, PubMed and ClinicalTrials.gov
(September 2013 to January 2014). The search terms
Coartem or Riamet or CGP56697 or CGP 56697 or
CGP-56697 or co-artemether or exafal, artemether or
artemeter, lumefantrine or benflumelol or benflumetol,
gametocyte, and combinations of these terms were used
to identify articles relating to AL and/or ACTand gameto-
cyte clearance/carriage. The search was limited to humans
and articles published in English. All resulting records
were screened and full-text articles read to determine
whether they included relevant gametocyte data.
Information extracted from each article included study
type and year, geographic location, study population
(number of children and/or adults), intervention evaluated,
gametocyte diagnostic method, sampling schedule for gam-
etocyte data, key data regarding gametocyte carriage and
malaria transmission, and key conclusions regarding effects
of AL (and other interventions as appropriate).
The limitations of analysing data from clinical trials that
involved population groups of different ages, immune status,
number of doses of AL treatment regimens, formulations,
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signs as well as diagnostic approaches, are recognized
and taken into account in the categorization of related
datasets and interpretation of the inferences from the
review.
Results
From a total of 175 records initially identified, more than
half were considered not relevant (i e, did not include data
on gametocyte clearance/carriage) or were duplicates,
leaving 62 relevant articles for review (Figure 2). These
were published between 1998 and January 2014 and
included randomized, double-blind and randomized
open-label trials (phases II–IV), non-interventional ob-
servational studies, single-/multi-centre reports, retro-
spective analyses of previously conducted efficacy studies,
pooled analyses, previously published systematic reviews,
reviews, and mini-reviews.
Of the 62 records identified, most (38) reported data
for children (aged four months to 15 years), 17 included
data for both children and adults, and four for adults
only (the three additional reports were general reviews).
The majority (45) of studies reported data for African
countries. Other study locations included Asia, Thailand,
India, Cambodia, Colombia, and Europe. Most reports
(42) noted the use of microscopy alone to detect game-
tocytes. An additional 12 reports utilized both micros-
copy and polymerase chain reaction (PCR) techniques or2 additional records identified through
other sources
64 full-text articles reviewed
111 records considered not relevant
or duplicates
2 further articles considered
not relevant
62 articles included in systematic review
Database searches identified:
169 records (Jan. 1996–Sept. 2013)
+ 4 records (Sept. 2013–Jan. 2014)
Figure 2 Overview of number of records identified, discarded
and included within the systematic review.compared one approach with the other, and three used
PCR alone (in the remaining five reports, details of the
gametocyte diagnostic technique were not stated or not
applicable). Five of the reports (encompassing three
studies in two settings) also included the use of mos-
quito feeding assays to detect gametocyte infectiousness
to mosquitoes.
Key details relating to all studies are listed in Additional
file 1 [8,9,11-15,17-19,21-72].
Effects of artemether-lumefantrine on gametocyte
clearance and malaria transmission
Studies that report the effects of AL (in the absence
of a comparator treatment) on gametocyte carriage/
clearance are reviewed below and summarized in
Table 1 [28,30,37,47,53,54,62,64,68,70] (and Additional
file 2 [28,30,37,47,53,54,62,64,68,70]). Unless otherwise
stated, all data discussed relate to patients with uncom-
plicated P. falciparum malaria.
Rapid clearance of gametocytes has been demonstrated
following treatment with AL in several geographic re-
gions in adults and children. In one of the earliest stud-
ies to report the gametocytocidal properties of AL [70],
the median time to gametocyte clearance following treat-
ment with AL was 72 hours (three days). The largest data-
set evaluating AL therapy to date is provided by a pooled
analysis of seven studies conducted over the period 1996
to 2007 involving 1,332 children and 647 adults [30]. Six
of the studies were conducted in malaria-endemic areas
(four in Thailand and two in Africa) [70,73-77], and the
other in non-immune adult travellers in Europe and
non-endemic regions of Colombia [54]. Treatment with
AL was associated with a rapid reduction in (micro-
scopically determined) gametocyte carriage (from 5.1%
of children with gametocytes at baseline to 0.9% after
day 7, and from 9.7% of adults at baseline to 4.2% after
day 7) (Figure 3) [30].
In the study of 165 non-immune travellers in Europe
and non-endemic regions of Colombia [54], the propor-
tion of adults with gametocytes was reduced following
treatment with AL so that no patient had gametocytes
after day 7. An earlier pooled analysis of eight studies
[64] suggested a more rapid clearance of gametocytes
following treatment with a six-dose AL regimen than
with a four-dose regimen in 544 children ≤12 years; a
lower proportion of patients with gametocytes was ob-
served up to day 7 following the six-dose regimen and
this effect seemed to be maintained at day 28 (0.3% of
patients receiving the six-dose regimen vs 3% on the
four-dose regimen had circulating gametocytes at days
15 to 28; p < 0.05).
The above data are supported by other obser-
vations in children and adults, as detailed in Table 1
[28,30,37,47,53,54,62,64,68,70].
Table 1 Effects of artemether-lumefantrine on gametocyte carriage/clearance - summary of key conclusions*
Reference Study description Study population Key conclusions
Makanga et al. [30] Pooled analysis of 7 studies
conducted between 1996-2007
Pooled population: 647 adults
and 1,332 children
AL showed high cure rates and rapid resolution of
parasitaemia, fever, and gametocytaemia in adults and
children
Gbotosho et al. [28] Anti-malarial efficacy studies in
Ibadan, southwestern Nigeria
2,585 children aged 0.5-15 years AL reduced the rate of gametocyte carriage in children
with acute falciparum infections at presentation and
shortened the duration of male gametocyte carriage
after treatment
Assefa et al. [37] 28-day therapeutic efficacy study
in Kersa District, Addis Ababa
90 adults and children The study showed a rapid decline in gametocytes with
treatment
The clearance rate was more rapid than that found in
other studies, which reported the presence of
gametocytes up to day 14 and beyond
John et al. [47] Kipsamoite (7 villages) and
Kapsisiywa (9 villages) in the
Nandi Hills district of Kenya
8,094 adults and children Treatment with AL (combined with IRS) reduced
gametocyte carriage and density in children compared
with the period prior to its implementation
Hatz et al. [54] Open-label, non-comparative
study in Europe and non-endemic
regions of Colombia
165 non-immune adult travellers Treatment with AL was effective in clearing
gametocytes by end of study in non-immune adults
Juma et al. [53] Randomized, controlled, open-label
study comparing AL tablets with
AL paediatric suspension in
Western Kenya
245 children AL tablets and the 3-dose suspension effectively cleared
gametocytes in these children
Makanga et al. [64] Pooled analysis of 8 studies to
compare 6-dose with 4-dose
AL regimen
544 children The 6-dose regimen is associated with a more rapid
clearance of parasites and a faster and more sustained
reduction in gametocyte carriage than the 4-dose
regimen
4 studies in Africa
4 studies in Thailand
Chanda et al. [62] Open label, one-arm prospective
evaluation of paediatric suspension
of AL in Zambia
91 children (<10 kg) AL paediatric suspension was associated with a
significant and rapid reduction in gametocytes
Barnes et al. [68] Open-label in vivo study in
KwaZulu-Natal province, South
Africa, to determine therapeutic
efficacy of a 6-dose regimen of AL
100 adults AL contributed to a marked and sustained decrease in
malaria cases, admissions, and deaths, by greatly
improving clinical and parasitological cure rates and
reducing gametocyte carriage
Lefèvre et al. [70] Randomized, open-label, parallel
group 4-week trial in Thailand
219 adults and children with
multidrug-resistant P. falciparum
malaria
AL rapidly cleared gametocytes in multidrug-resistant
P. falciparum malaria
Further data on these studies can be found in Additional file 2.
AL: artemether-lumefantrine; IRS: indoor residual spraying.
*References for this review were identified through searches as documented in the Methods section of this publication. Information extracted from each article
included study type and year, geographic location, study population (number of children and/or adults), intervention evaluated, gametocyte diagnostic method,
sampling schedule for gametocyte data, key data regarding gametocyte carriage and malaria transmission, and key conclusions regarding effects of AL.
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anti-malarials on gametocyte carriage and malaria
transmission
Artemether-lumefantrine versus dihydroartemisinin-piperaquine
There have been mixed reports regarding the comparative
effect of AL and dihydroartemisinin-piperaquine (DP) on
post-treatment gametocyte carriage. Key findings are sum-
marized in Table 2 [12,26,32,44,50,52,57] (and Additional
file 3 [12,26,32,44,50,52,57]).
DP was reported to be superior to AL in reducing
gametocytaemia, with a longer duration of microscopic-
ally detected gametocyte carriage reported after AL than
DP in two randomized studies (from the same group) of
408 and 417 Ugandan children in areas of moderate [50]and high transmission intensity [57], respectively. How-
ever, data from other studies suggest a similar or shorter
duration of gametocyte carriage after treatment with AL
than with DP. In an analysis of seven randomized trials,
treatment with DP was compared with AL and other
ACT [44]. Clearance of gametocytaemia (microscopically
determined) was slower with DP than the other agents,
both overall and within individual sites. At day 3 follow-
ing treatment with DP (n = 211), 7.4% of patients still
had gametocytaemia compared with 1.8% of patients
treated with AL (n = 210). A large longitudinal clinical
trial of 351 Ugandan children (≥ four months; 100 HIV-
unexposed, 203 HIV-exposed and 48 HIV-infected) re-
ported an 85% increased risk of microscopically
Table 2 Effects of artemether-lumefantrine versus dihydroartemisinin-piperaquine on gametocyte carriage/clearance
Reference Study description (location) Study population Gametocyte
diagnostic method
Key conclusions
Kakuru et al. [12] Open-label randomized controlled
trial (AL vs DP + TS prophylaxis)
in Tororo district, Uganda
351 children
(aged ≥4 months)
Microscopy Rate of gametocyte clearance was
more than 2-fold greater with




Sawa et al. [26] Randomized, open label trial
(AL vs DP) in Mbita, Western Kenya







AL was associated with a significantly
shorter duration of gametocyte carriage,
and a significantly shorter time to
gametocyte clearance than DP
Malaria transmission to mosquitoes was
significantly lower after AL treatment
than after DP
Smithuis et al. [32] Open-label randomized trial
(comparison of ACT, including
DP vs AL) in Myanmar
>800 adults and
children
Microscopy Gametocyte carriage was variable
following treatment with different ACT,
although all rates were higher with DP
than other ACT regimens, including AL
Zwang et al. [44] Analysis of 7 open-label randomized
comparative studies (DP vs AL and
vs other ACT) in Northwest Thailand,




Microscopy Clearance of gametocytaemia was slower
in DP groups than in the comparators,
overall and in individual sites
Yeka et al. [50] Randomized study (AL vs DP) in Western




Microscopy Patients treated with DP had a lower
risk of developing gametocytaemia than
those treated with AL after therapy
Mens et al. [52] Randomized study (AL vs DP) in Mbita,
Western Kenya, use of QT-NASBA
146 children Microscopy A more rapid reduction in gametocytes
was observed with AL than with DP
QT-NASBA
QT-NASBA provides a far more sensitive
method than microscopy in gametocyte
detection
Kamya et al. [57] Randomized single-blinded study
(AL vs DP) in Apac, District, Uganda




Microscopy Patients treated with DP had a lower
risk of recurrent parasitaemia due to
non-falciparum species, and development
of gametocytaemia compared with
patients treated with AL
Further data on these studies can be found in Additional file 3.
ACT: artemisinin-based combination therapy; AL: artemether-lumefantrine; DP: dihydroartemisinin-piperaquine; HR: hazard ratio; QT-NASBA: quantitative real-time























































































Figure 3 Reduction in gametocyte carriage with artemether-lumefantrine in adults and children with uncomplicated Plasmodium
falciparum malaria [30]. Giemsa-stained thick blood smears were examined for gametocytes. AL: artemether-lumefantrine; mITT: modified
intention-to-treat.
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Figure 4 Time to disappearance of gametocytes in gametocyte-
positive individuals (by quantitative real-time nucleic acid
sequence-based amplification) at enrolment following treatment
[26]. AL: artemether-lumefantrine (n = 32); DP: dihydroartemisinin-
piperaquine (n = 35). (Sourced from Sawa et al. 2013, with
permission [26]).
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AL during the 28 days following treatment [12]. The rate
of gametocyte clearance was more than two-fold greater
with AL than DP (hazard ratio (HR) 2.20; p < 0.001) after
adjusting for prophylaxis with TS, age and recurrent
parasitaemia.
In a comparison of ACT (AL, AS-MQ, AS-AQ, and
DP) in >800 adults and children from Myanmar, gam-
etocyte carriage rates varied widely following treatment
with the different regimens, although all were lower than
with DP. Notably, further reductions (approximately 12
times lower) in gametocyte carriage rates were observed
with all ACT regimens following the addition of prima-
quine [32].
The variation in post-treatment gametocyte carriage
across studies may be due to different types of analyses
and also the low sensitivity of microscopy for detection
of gametocytes; it is now well acknowledged that only a
fraction of gametocytes can be detected by this method
[11]. For example, a randomized study of 146 Kenyan
children previously utilized quantitative real-time nucleic
acid sequence-based amplification (QT-NASBA) to
evaluate the efficacy and effectiveness of AL vs DP in the
treatment and control of malaria transmission. Notably,
gametocytes were detected in a significantly higher pro-
portion of patients than were detected by microscopy
alone and a significantly greater risk of gametocyte car-
riage was reported after DP than AL treatment [52].
Further evidence of the importance of the gametocyte
diagnostic method is provided by a randomized trial in
298 African children (aged six months to ten years) who
were treated with AL or DP. A highly sensitive molecu-
lar assay was used to assess gametocyte carriage, and
mosquito-feeding assays were used to determine infec-
tiousness to mosquitoes [26]. The gametocytocidal effect
of AL immediately after treatment was larger than that
of DP. There was no difference between treatment arms
in enrolment gametocyte prevalence (9.7% by micros-
copy and 71.3% by QT-NASBA). AL was associated with a
significantly shorter mean duration of gametocyte carriage
than DP (5.5 vs 15.3 days, respectively; p = 0.001). For in-
dividuals who were gametocyte-positive (by QT-NASBA)
prior to treatment, the time to disappearance of gameto-
cytes was significantly shorter for the AL group vs the DP
group (HR 2.35) (Figure 4) [26]. In terms of gametocyte
transmission to mosquitoes that fed on post-treatment
blood samples, 1.9% (43/2293) became infected from AL-
treated children and 3.5% (83/2371) were infected from
the blood of DP-treated children (p = 0.06).
Artemether-lumefantrine versus other artemisinin
combination therapy
The effects of AL on gametocyte carriage and malaria
transmission to mosquitoes have also been comparedwith those of other ACT. Key findings are summarized in
Table 3 [31,33,36,40,63,65,69,70] (and Additional file 4
[31,33,36,40,63,65,69,70]) and discussed below. For some
ACT, the findings have to be interpreted with some caution
since resistance to partner drugs (e g. AQ, sulphadoxine-
pyrimethamine [SP]) will likely affect gametocyte clearance
time after administration.
In the first comparative trial of the efficacy of three
combination therapies in Bangladesh, AL and MQ +AS
ACT effectively prevented the development of gameto-
cytes whereas chloroquine + sulphadoxine-pyrimeth-
amine (CQ + SP) did not [67]. At 42 days of follow-up,
46% of patients in the CQ + SP group had gametocytes
at one or more visits, compared with 0.8% of patients
treated with MQ +AS and 2.5% of patients who received
AL. Similarly, a large (n = 1,717) randomized, four-arm
trial of children (aged four to 59 months) in Tanzania re-
ported substantially fewer gametocytes in two artemisinin-
containing combination groups (AL and AQ+AS) than in
the non-artemisinin-containing AQ+ SP combination
group at day 14 [65]. Gametocyte prevalence at day 14
was significantly reduced from that recorded at patient
presentation in the artemisinin groups, but not with
the non-artemisinin-containing regimens: 6% with AL,
12% with AQ + AS, 26% with AQ + SP, and 19% with
AQ alone.
In a randomized, open-label phase IV study, a reduc-
tion in gametocyte carriage was demonstrated in AL and
AS + AQ treatment arms, although clearance was more
rapid following AL than AS + AQ; gametocytes had dis-
appeared by day 14 in the AL group and by day 21 in
the AS + AQ group [36]. An earlier study of 298 children
Table 3 Effects of artemether-lumefantrine versus dihydroartemisinin-piperaquine and other artemisinin-based combination therapy on gametocyte
carriage/clearance
Reference Study description (location) Study population Gametocyte
diagnostic method
Key conclusions
4ABC Study Group [31] Randomized head-to-head comparison
(AL vs AQ + AS vs DP vs CD + A) in
7 sub-Saharan African countries
4,116 children
(aged 6–59 months)
Microscopy Gametocyte prevalence during follow-up was significantly lower
and carriage time significantly shorter in children who received
AL than in those treated with DP, AQ + AS, or CD + A
Faye et al. [36] Multisite, randomized, open-label phase
IV study in Dakar, Senegal, Ivory Coast
322 patients
(aged >7 years)
Microscopy Anti-gametocyte activity was more effective and rapid during
treatment with AL than AS + AQ
AL vs AS + AQ
Tshefu et al. [33] Phase III, parallel-group, double-blind,
randomized, non-inferiority trial at 7 sites
in Africa and 3 sites in Southeast Asia
1,272 adults and children MicroscopyPCR Fixed-dose P-AS showed high clinical and parasitological response
rates and rapid parasite clearance
(AL vs P-AS)
Zwang et al. [40] Systematic review of comparative and
non-comparative clinical trials in sub-Saharan
Africa (16 countries, 33 sites)
11,700 patients
(AL administered to 1,319
patients at 11 study sites)
Microscopy Compared with AS + AQ, the risk of appearance of gametocytes
was higher and the carriage duration was longer with the non-ACT
than with AL and DP ACT regimens
(AL vs AS + AQ vs AQ vs CQ + SP vs AQ + SP
vs DP vs AS + SP)
van den Broek et al. [63] Comparator study in Kindamba, Republic of
Congo
298 children Microscopy AL was clinically more effective than AS + SP and AS + AQ in
these children
(AL vs AS + AQ vs AS + SP)
van den Broek et al. [67] Open-label, randomized, 3-arm efficacy
trial in Chittagong, Bangladesh
364 adults and children Microscopy ACTs block the development of new gametocytes. This effect has
potential implications for the transmission of P. falciparum malaria
(AL vs MQ+ AS vs CQ + SP) In contrast, CQ + SP therapy does not affect gametocyte development




Microscopy Gametocyte prevalence at day 14 in the ACT groups was significantly
reduced compared with presentation
(AL vs AQ vs AQ + AS vs AQ + SP) ACT combinations led to lower gametocyte carriage, suggesting lower
infectiousness with these treatments than with other combinations
Koram et al. [69] Comparator study in Hohoe and
Navrongo, Ghana
168 children (<5 years) Microscopy The prevalence of gametocytaemia was highest within the SP group,
in-line with evidence to suggest that using SP alone increases prevalence
of gametocytes, with possible increase in malaria transmission
(AL vs AS + AQ vs CQ vs SP)
Gametocyte prevalence was lowest with AL and AS + AQ ACT regimens
Lefèvre et al. [70] Randomized, open-label, parallel group
4-week trial in Thailand
219 adults and children
with multidrug-resistant P.
falciparum malaria
Microscopy Gametocyte clearance was more rapid with AL than MQ + AS in these
children
(AL vs MQ+ AS)
Further data on these studies can be found in Additional file 4.
A: artesunate; ACT: artemisinin-based combination therapy; AL: artemether-lumefantrine; AQ: amodiaquine; AS: artesunate; CD: chlorproguanil-dapsone; CQ: chloroquine; DP: dihydroartemisinin-piperaquine;
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cyte carriage rate with AL, AS + AQ and AS + SP; an in-
crease in gametocytes was observed during the first two
days of treatment, but reduced during the four weeks of
follow-up, from 8 to 1% in the AL group, from 23 to 3%
in the AS + AQ group, and from 26 to 5% in the AS + SP
group [63]. These findings are consistent with those
from a study of 168 children (<five years) in Ghana;
treatment with AL was associated with a similar gameto-
cyte clearance rate as AQ + AS; gametocytaemia peaked
on day 1 (7.7% for AQ +AS and 11.8% for AL) and de-
clined to 2% for both ACT on days 7 and 14 [69].
A systematic review covering the periods February
1999 to December 2006 reported data from 11,700 pa-
tients from 16 countries at 33 sites in sub-Saharan Africa
[40]. Comparative studies included 5,987 patients who
received AS + AQ and 5,713 treated with other anti-
malarials (AL was administered at 11 sites to 1,319 pa-
tients). The overall median clearance time was day 14 in
patients treated with AS + AQ, but varied widely by site
(day 1 to 28). Compared with AS + AQ groups, the risk
of gametocyte appearance post-admission was signifi-
cantly higher with AQ, CQ + SP and AQ + SP, lower with
AL and DP and not different with AS + SP. The overall
carriage rate was 57% shorter with AL compared with
AS + AQ.
Further data are provided by a randomized trial con-
ducted in >4,100 children (aged six to 59 months) from
12 sites in sub-Saharan Africa [31]. Microscopically de-
termined gametocyte prevalence during follow-up was
significantly lower in children who received AL than in
those treated with DP, AQ + AS or chlorproguanil-
dapsone-artesunate (CD +A) in this large head-to-head
comparison of four ACT (AL, AQ+AS, DP and CD+A).
Gametocyte carriage time was also significantly shorter
with AL than with AQ+AS and DP in this trial. However,
in a randomized phase III trial of fixed-dose pyronaridine
(P)-AS vs AL in 1,272 children and adults from Africa and
Asia, the rate of gametocyte clearance did not significantly
differ between groups (mean gametocyte clearance time:
14.7 hours with P-AS and 25.2 hours with AL) [33].Artemether-lumefantrine versus non-ACT
Non-ACT, and particularly SP and CQ, appear to have
only partial activity against immature gametocytes [61],
resulting in a relatively large proportion of individuals
who remain gametocyte-positive after treatment. Signifi-
cant increases in gametocyte carriage have been reported
in some studies following non-ACT treatment [58,72].
Compared with non-ACT, AL has been associated with
significantly reduced gametocyte carriage [51,66], and
reduced infectivity to mosquitoes [66] (Additional file 1
[8,9,11-15,17-19,21-72]).Effects of screening and treatment of asymptomatic
carriers on population gametocyte carriage
Large proportions of P. falciparum infections are asymp-
tomatic in malaria-endemic countries. Asymptomatic
carriers can carry high levels of gametocytes, resulting in
an infectious parasite reservoir that can infect newly
hatched mosquitoes. While the role of asymptomatic
carriers in disease transmission is currently unclear, it
follows that the identification and treatment of asymp-
tomatic carriers could reduce this pool of parasites and
thus reduce transmission of malaria. This hypothesis is
supported by modelling studies. A modelling and simu-
lation analysis of community screening and treatment of
asymptomatic carriers with AL predicted that treatment
should clear asymptomatic infection and transmission of
disease if carried out in the period prior to the transmis-
sion season [78]. The short- and long-term impact of
mass treatment strategies in different endemic transmis-
sion settings was explored using a previously developed
mathematical model. The data indicated that in small
populations, temporary elimination may be feasible with
several rounds of mass treatment together with vector
control [5].
A relatively small pilot project conducted in a rural
area of southern Zambia also demonstrated that active
case detection (using the rapid diagnostic test (RDT)) is
feasible and can identify reservoirs of asymptomatic in-
fection and gametocyte carriers [34]. A large controlled,
cluster-randomized trial was therefore conducted to de-
termine the impact of identification (through commu-
nity screening using the RDT) and AL treatment of
asymptomatic carriers of P. falciparum on the number
of cases of symptomatic malaria over a 12-month period
compared with no RDT or AL treatment [24]. A total of
14,000 patients from 18 villages in Burkina Faso partici-
pated in the trial that consisted of four community
screening campaigns, the first three before the rainy sea-
son in which the RDT was used to identify asymptom-
atic carriers and who were treated with AL from day 1,
and the fourth after the rainy season at approximately
12 months. Overall, 96.1% of the population in the inter-
vention arm who consented to participation were tested
by RDT. A significantly lower mean gametocyte carriage
was observed at day 1 of campaigns 2 and 3 following
AL treatment vs controls (0.7 vs 5.4%; p < 0.0001, and
0.5 vs 5.8%; p < 0.0001), indicating a reduction in the
parasite reservoir. However, this effect was not sustained
as there was little difference between intervention and
control arms in gametocyte prevalence at day 1 of cam-
paign 4 (4.9 vs 5.1%; NS). Therefore, the effect on gam-
etocyte carriage did not translate into interruption of
malaria transmission or reduction in symptomatic cases.
There are likely to be several reasons why the findings
from this study do not reflect the earlier simulation
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vectors from surrounding villages not involved in the
study and the high transmission intensity. In this re-
spect, in a limited study of this type, it would be prob-
lematic to prevent the introduction of disease by
population migration and the highly mobile mosquito
vector. Indeed, over 60 villages that were not being stud-
ied were in close proximity to the communities receiving
intervention. Another confounding factor that might ex-
plain the ability to determine a benefit associated with
AL vs control might be the fact that all participants in
the trial were provided with an ITN, regardless of the
intervention they received.
Taking this all into account, it is still possible that
mass treatment with a drug that has effects on gameto-
cyte carriage could translate into tangible clinical bene-
fits. However, any future studies investigating this
further will need to consider the learnings from this
study conducted in Burkina Faso.
Challenges
One major challenge with the findings reviewed here is
the ability to make direct comparisons between studies
that have been conducted using different methodologies,
at different time periods, in different populations, and
from geographic regions that differ with respect to trans-
mission intensity and patterns of drug resistance.
Added to the above challenges are difficulties in the
interpretation of gametocyte data from older studies that
are dependent on microscopy methods alone (see
below), studies that differ in terms of the timing of sam-
pling for analysis of gametocyte data (i e. pre-specified
sampling points, that do not allow for fluctuations in in-
fectiousness, vs sampling throughout the study), and
studies that did not set out to determine gametocyte via-
bility and are associated with independent gametocyte
data analyses. Diagnostic tests for gametocytaemia have
evolved over recent years; early gametocyte data were
based solely on microscopy that was considered the gold
standard in malaria diagnosis for many years, and nu-
merous studies have relied solely on this method to
evaluate gametocyte data. However, the development of
highly sensitive and specific PCR-based methods, such
as the QT-NASBA technique, has led to far superior
gametocyte detection rates [11,26,52,79]; in the large
controlled, cluster-randomized trial of asymptomatic
carriers reviewed above, an eight-fold greater prevalence
of gametocytes was detected following quantitative re-
verse transcription-PCR compared with microscopy at
day 1 of campaign 4 [24]. As such, it is difficult to draw
definitive conclusions regarding the potential impact of
ACT on malaria transmission potential based on micros-
copy data alone. It is notable that in most (42/62; 68%)
of the studies identified by this literature search andreviewed here, gametocyte data are based solely on mi-
croscopy. However, it is also worth noting that despite
the use of different diagnostic approaches to estimate
baseline gametocyte counts and a range of other factors
affecting baseline gametocytaemia, the gametocytocidal
effect of AL is proportionately consistent across studies.
One further challenge, which is currently only partially
answered, is the viability and infectivity of gametocytes
following treatment. The majority of the studies ana-
lysed, with the exception of three studies in two settings
(western Kenya and the Gambia) [26,46,59,61,66], did
not have a study component (i e. feeding assays) that
evaluated the viability and infectivity of the gametocytes
that appear post treatment. Nevertheless, the limited
available data suggest that ACT, and AL treatment in
particular, are able to reduce the infectiousness of blood
samples to mosquitoes when compared with non-ACT
regimens [26,66].
The transmission abilities of sub-microscopic gameto-
cyte densities represents a further challenge that requires
investigation. Notably, the relative contribution to mal-
aria transmission appears to be similar for carriers with
sub-microscopic and microscopic gametocytaemia [59],
underlining the need for sensitive detection methods
that do not rely solely on microscopy.
In a randomized study of Kenyan children (n = 528),
QT-NASBA revealed a significant proportion of children
with sub-microscopic gametocytaemia (four-fold higher
than expected based on microscopy alone). Treatment
with AL did not significantly reduce the infectious pro-
portion of the population when compared with SP
monotherapy, but the percentage of mosquitoes that be-
came infected was lower (3.6%) following treatment with
AL than SP (6.9%) [61]. The authors concluded that
sub-microscopic gametocytaemia is common after treat-
ment, and the effect of ACT is moderate and does not
prevent post-treatment malaria transmission. There is
also emerging evidence that extended parasite clearance
time and residual sub-microscopic parasitaemia after
ACT treatment increases transmission to mosquitoes
and results in a higher risk of recurrent parasitaemia
[22]. In this study of Kenyan children, individuals with
residual parasitaemia following AL treatment had a two-
fold longer duration of gametocyte carriage (p = 0.0007),
were more likely to infect mosquitoes (p = 0.015) and to
have microscopically detectable parasitaemia during follow-
up (p < 0.001).
However, there may be conflicting factors in Kenya.
For example, this country has a relatively high preva-
lence of HIV [80], relatively high mortality in children
[81], almost omnipresent schistosomiasis co-infection in
children [82], and declining malarial transmission in
some areas [83]. In contrast, the Gambia, is a very differ-
ent setting with, for example, lower rates of HIV [84]. In
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vented transmission [66] at a time (2002) when malarial
transmission was considerably higher than it is today
[85,86]. Further data are required, therefore, to deter-
mine conclusively whether AL can reduce transmission
of malaria – and in which populations and settings. Data
are also required to compare the transmission-blocking
effects of AL vs other ACT.
Utilizing ACT such as AL within malaria eradication
strategies is also associated with a number of other chal-
lenges, such as balancing potential increased use of ACT
(e g, treatment of asymptomatic carriers) with rational
use and avoidance of resistance development. In this re-
gard, artemisinin resistance has been predicted to spread
more rapidly with increasing use of ACT, including
when used in mass drug administration programmes.
However, these predictions have mainly been based on
mathematical modelling [87,88]. These models suggest
that combinations of interventions are most effective for
successful elimination, and that adding primaquine to
ACT reduces the likelihood of artemisinin resistance de-
veloping. Therefore, while it has been argued that mul-
tiple rounds of mass drug administration (e g, with an
ACT and gametocytocidal agent) could potentially result
in at least temporary elimination of malaria if used
alongside vector control [5], the careful selection of anti-
malarials for this use would be crucial in order to
minimize the risk of drug selection pressure and develop-
ment of resistance. In this regard, it is crucial to ensure
that any drugs that are chosen for such a programme are
administered appropriately to avoid suboptimal drug ex-
posure, which could lead to breakthrough resistance. This
issue is highlighted by a recent systematic review, which
found that ACT adherence levels varied from <30% for
general ACT use in Kenya, to up to 100% adherence to
AL in Malawi [89].
Potential contribution of artemether-lumefantrine to
future malaria elimination strategies
It is widely accepted that ACT will have a key role to
play in future malaria elimination strategies. The spe-
cific place of different ACT, including AL, is the subject
of much ongoing research and will undoubtedly be
dependent on different demographic and geographical
scenarios, and include consideration of factors such as
endemicity levels, transmission intensity, resistance pat-
terns to partner drugs, availability of specific drugs and
rapid, cost-effective diagnostic testing kits.
Much of the gametocyte data reviewed here indicate
that AL does possess gametocytocidal properties; rapid
reduction in gametocyte carriage has been reported in
studies of almost 6,000 children and adults, and possible
interruption of malaria transmission has been observed
when combined with indoor residual spraying in studiesinvolving >8,000 children and adults. Superior gametocyte
clearance rates and reduced infectiousness to mosquitoes
has been demonstrated with AL when compared with DP
in studies of >2,000 children and adults, and when com-
pared with other ACT in studies involving >18,000 chil-
dren and adults.
These findings suggest that AL is a logical ACT option
for use in future malaria elimination programmes, pos-
sibly combined with a further gametocytocidal agent,
such as primaquine (see below) [21], or in combination
with preventative measures such as vector control (e g,
ITNs and long-lasting insecticide-treated nets) and po-
tentially future malaria transmission-blocking vaccines.
Based on the recent data of Sawa et al. [26], AL appears
to be a valuable ACT to reduce community-wide trans-
mission of P. falciparum malaria, especially in areas of
lower endemicity, while DP may be best suited to the
prevention of re-infections in areas of higher endemicity.
However, the choice of which ACT to use – AL or DP –
is not clear cut. A recent systematic review suggested
that DP is superior to AL in preventing further parasit-
aemia in Africa, although PCR-adjusted treatment failure
was below 5% for both ACT [90]. Additionally, DP ap-
peared to have a longer prophylactic effect on new infec-
tions. Nevertheless, findings presented here indicate that
AL is more effective than DP in terms of gametocyte
clearance, and this is most evident in the first few weeks
post-treatment. This benefit may outweigh the relatively
shorter prophylactic effect of AL.
The gametocytocidal medicine primaquine may have an
important role in a malaria elimination campaign. ACT is
recommended for individuals of all ages to be used with a
single dose of primaquine (0.25 mg base/kg) to treat P. fal-
ciparum malaria [1,16]. Ideally, a glucose-6-phosphate de-
hydrogenase (G6PD) test is required prior to initiating
treatment with primaquine, but this may not be feasible in
the majority of malaria-endemic countries [1]. A recent
study confirmed that primaquine is effective in reducing
gametocyte carriage [21], although there are still questions
remaining with respect to use in areas of high or moderate
transmission, optimum timing of administration and use
in asymptomatic vs symptomatic infections. In spite of
these outstanding questions, AL has also been associated
with a good safety profile in G6PD-deficient individuals
[45], suggesting a possible role for AL combined with
primaquine in this setting. Additionally, based on available
data, the gametocytocidal effect of AL may synergize with
that of primaquine when used in combination [33]. How-
ever, this area requires further research, given that the effi-
cacy of primaquine is CYP2D6 dependent [91].
Conclusions
It is anticipated that AL (along with other ACT) will con-
tinue to play a vital role in the treatment of uncomplicated
Makanga Malaria Journal 2014, 13:291 Page 12 of 15
http://www.malariajournal.com/content/13/1/291falciparum malaria [90]. Like other ACT, AL maintains
high efficacy against the asexual stage of falciparum para-
sites, which largely reduces parasitaemia in a population
through treatment. Based on the data reviewed here, the
effect on asexual parasites is complemented by a pro-
nounced reduction in gametocyte carriage in both symp-
tomatic patients and asymptomatic carriers. Indeed, it
appears that AL may be the most potent ACT in terms of
clearing gametocytes.
Considering all of the above, AL may play an import-
ant role in the drive towards malaria elimination. How-
ever, there is currently incomplete evidence as to
whether residual transmission persists after ACT. Add-
itionally, while there is some evidence that country-wide
implementation of AL can contribute to reducing trans-
mission compared with non-ACT [68], this was not con-
firmed in a cluster randomized trial in an area of very
high transmission intensity in Burkina Faso [24]. What
is clear is that if AL is used widely to reduce transmis-
sion, then strategies should be sought to protect against
AL drug resistance. The use of AL with single dose
primaquine could be helpful but requires further evalu-
ation. More data is needed to help to determine the level
gametocyte infectivity post treatment and the potential
role of AL in malaria elimination programmes, and to
compare AL with other ACT, including DP.
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